Table 2.

Relative hazard of death in HNSCC patients based on platelet counts

Variables	Low (<150) N = 67	Low normal (150–229) N = 361	Mid-normal (230–314) N = 379	High normal (315–399) N = 169	HIGH (≥400) N = 75
Number dead (%)	37 (55)	150 (42)	146 (39)	105 (62)	53 (71)
Median Survival Months (95% CI)	37.7 (20.7- 84.8)	64.0 (53.6-78.9)	74.7 (60.7 100.4)	23.8 (17.7 - 36.7)	16.3 (11.8 -29.2)
p-value for difference					<0.0001
Overall Survival
Unadjusted HR (95% CI)	1.52 (1.06-2.18)	1.07 (0.85-1.34)	1.0 (reference)	1.98 (1.54-2.55)	2.64 (1.92 -3.61)
Adjusted HR (95% CI)	1.50 (0.96-2.35)	1.25 (0.93-1.68)	1.0 (reference)	2.20 (1.58-3.05)	2.37 (1.60-3.50)
HR (95% CI) by Stage
I (n = 103)	0.41 (0.05-.3.31)	1.18 (0.33-4.20)	1.0 (reference)	1.60 (0.27-9.54)	0.35 (0.03-4.18)
II (n = 95)	1.99 (0.52-7.67)	1.40 (0.57-3.38)	1.0 (reference)	1.54 (0.48-4.99)	1.83 (0.45-7.40)
III (n = 146)	0.74 (0.16-3.40)	1.32 (0.62-2.82)	1.0 (reference)	2.43 (0.91-6.50)	1.86 (0.53-6.45)
IV (n = 478)	2.33 (1.34-4.10)	1.18 (0.78-1.78)	1.0 (reference)	2.50 (1.66-3.76)	2.47 (1.55-2.93)

Adjusted model controls for age, race, site, grade, treatment, smoking and stage.

P for interaction between stage and classes of platelets p = 0.31.